Cargando…
(181) A Single-Center Experience with More Than 200 Lung Transplant Recipients with COVID-19 Infection
PURPOSE: There still have been limited data regarding COVID-19 in lung transplant recipients (LTR). We sought the outcomes after COVID-19 infection in LTR using our largest dataset. METHODS: We analyzed our database of LTR who were diagnosed with COVID-19 between March 26, 2020 and September 6, 2022...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068077/ http://dx.doi.org/10.1016/j.healun.2023.02.197 |
_version_ | 1785018611062013952 |
---|---|
author | Kehara, H. Johnson-Whiting, A. Iturra, S. Raman, R. Yanagida, R. Krishan, K. Kashem, A. Cordova, F. Criner, G. Toyoda, Y. Shigemura, N. |
author_facet | Kehara, H. Johnson-Whiting, A. Iturra, S. Raman, R. Yanagida, R. Krishan, K. Kashem, A. Cordova, F. Criner, G. Toyoda, Y. Shigemura, N. |
author_sort | Kehara, H. |
collection | PubMed |
description | PURPOSE: There still have been limited data regarding COVID-19 in lung transplant recipients (LTR). We sought the outcomes after COVID-19 infection in LTR using our largest dataset. METHODS: We analyzed our database of LTR who were diagnosed with COVID-19 between March 26, 2020 and September 6, 2022. First, we investigated the clinical outcomes of the all cohort, and then divided them into three groups depending on their time of diagnosis (Dx, 1st wave: 03/2020-10/2020, 2nd: 11/2020-11/2021, and 3rd: 12/2021-09/2022), and compared these results. RESULTS: 210 LTR (median age, 67; 67% male) were enrolled. The median time from LT to their Dx was 2.1 years. Five patients had the Dx during their index admission for LT whereas all of them died during their admission. One hundred forty patients (67%) required readmission, including 46 (33%) receiving ICU management. Among those hospitalized, 35 patients (25%) were intubated and 7 patients (5%) were placed on VV ECMO. Overall survival was 67% at 1 year and 59% at 2 years post-Dx (Figure 1). While 89 patients (42%) were unvaccinated at the time of their Dx, 121 patients (58%) were vaccinated including 63 patients (30%) with boosters. Although survival was significantly better in the 3rd period (Figure 1), hospital mortality has not changed (1st: 28%, 2nd: 38%, 3rd: 28%). Vaccination was the only significant predictor for hospital admission (initial series vs none: odds ratio [OR] 0.22; boosters vs none: OR 0.27). Age ≥ 70 years (OR 2.87) and initial series of vaccines (vs None: OR 3.10; vs boosters: OR 3.71) contribute to hospital mortality as an independent predictor. CONCLUSION: Survival post-COVID-19 infection in LTR continues to improve, however, hospital mortality remains remarkably high with 30%. Whereas vaccination appears to have been impactful in preventing hospital admission, vaccination also has demonstrated inconsistent results for reducing hospital mortality. Further research is continued focused on how to better identify the high risk LTR who may lead to the mortality. |
format | Online Article Text |
id | pubmed-10068077 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100680772023-04-03 (181) A Single-Center Experience with More Than 200 Lung Transplant Recipients with COVID-19 Infection Kehara, H. Johnson-Whiting, A. Iturra, S. Raman, R. Yanagida, R. Krishan, K. Kashem, A. Cordova, F. Criner, G. Toyoda, Y. Shigemura, N. J Heart Lung Transplant Article PURPOSE: There still have been limited data regarding COVID-19 in lung transplant recipients (LTR). We sought the outcomes after COVID-19 infection in LTR using our largest dataset. METHODS: We analyzed our database of LTR who were diagnosed with COVID-19 between March 26, 2020 and September 6, 2022. First, we investigated the clinical outcomes of the all cohort, and then divided them into three groups depending on their time of diagnosis (Dx, 1st wave: 03/2020-10/2020, 2nd: 11/2020-11/2021, and 3rd: 12/2021-09/2022), and compared these results. RESULTS: 210 LTR (median age, 67; 67% male) were enrolled. The median time from LT to their Dx was 2.1 years. Five patients had the Dx during their index admission for LT whereas all of them died during their admission. One hundred forty patients (67%) required readmission, including 46 (33%) receiving ICU management. Among those hospitalized, 35 patients (25%) were intubated and 7 patients (5%) were placed on VV ECMO. Overall survival was 67% at 1 year and 59% at 2 years post-Dx (Figure 1). While 89 patients (42%) were unvaccinated at the time of their Dx, 121 patients (58%) were vaccinated including 63 patients (30%) with boosters. Although survival was significantly better in the 3rd period (Figure 1), hospital mortality has not changed (1st: 28%, 2nd: 38%, 3rd: 28%). Vaccination was the only significant predictor for hospital admission (initial series vs none: odds ratio [OR] 0.22; boosters vs none: OR 0.27). Age ≥ 70 years (OR 2.87) and initial series of vaccines (vs None: OR 3.10; vs boosters: OR 3.71) contribute to hospital mortality as an independent predictor. CONCLUSION: Survival post-COVID-19 infection in LTR continues to improve, however, hospital mortality remains remarkably high with 30%. Whereas vaccination appears to have been impactful in preventing hospital admission, vaccination also has demonstrated inconsistent results for reducing hospital mortality. Further research is continued focused on how to better identify the high risk LTR who may lead to the mortality. Published by Elsevier Inc. 2023-04 2023-04-03 /pmc/articles/PMC10068077/ http://dx.doi.org/10.1016/j.healun.2023.02.197 Text en Copyright © 2023 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Kehara, H. Johnson-Whiting, A. Iturra, S. Raman, R. Yanagida, R. Krishan, K. Kashem, A. Cordova, F. Criner, G. Toyoda, Y. Shigemura, N. (181) A Single-Center Experience with More Than 200 Lung Transplant Recipients with COVID-19 Infection |
title | (181) A Single-Center Experience with More Than 200 Lung Transplant Recipients with COVID-19 Infection |
title_full | (181) A Single-Center Experience with More Than 200 Lung Transplant Recipients with COVID-19 Infection |
title_fullStr | (181) A Single-Center Experience with More Than 200 Lung Transplant Recipients with COVID-19 Infection |
title_full_unstemmed | (181) A Single-Center Experience with More Than 200 Lung Transplant Recipients with COVID-19 Infection |
title_short | (181) A Single-Center Experience with More Than 200 Lung Transplant Recipients with COVID-19 Infection |
title_sort | (181) a single-center experience with more than 200 lung transplant recipients with covid-19 infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068077/ http://dx.doi.org/10.1016/j.healun.2023.02.197 |
work_keys_str_mv | AT keharah 181asinglecenterexperiencewithmorethan200lungtransplantrecipientswithcovid19infection AT johnsonwhitinga 181asinglecenterexperiencewithmorethan200lungtransplantrecipientswithcovid19infection AT iturras 181asinglecenterexperiencewithmorethan200lungtransplantrecipientswithcovid19infection AT ramanr 181asinglecenterexperiencewithmorethan200lungtransplantrecipientswithcovid19infection AT yanagidar 181asinglecenterexperiencewithmorethan200lungtransplantrecipientswithcovid19infection AT krishank 181asinglecenterexperiencewithmorethan200lungtransplantrecipientswithcovid19infection AT kashema 181asinglecenterexperiencewithmorethan200lungtransplantrecipientswithcovid19infection AT cordovaf 181asinglecenterexperiencewithmorethan200lungtransplantrecipientswithcovid19infection AT crinerg 181asinglecenterexperiencewithmorethan200lungtransplantrecipientswithcovid19infection AT toyoday 181asinglecenterexperiencewithmorethan200lungtransplantrecipientswithcovid19infection AT shigemuran 181asinglecenterexperiencewithmorethan200lungtransplantrecipientswithcovid19infection |